Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 11, 2006

View Archived Issues

Preclinical antidementia profile of FK-962

Antiinflammatory activity of a new SSAO/VAP-1 inhibitor

Aromatase a target for non-small cell lung cancer treatment

Oregovomab active in recurrent ovarian cancer

Encouraging results seen with pegylated arginine deiminase in metastatic melanoma

Pharmexa sets out development plans for GV-1001

Nuvelo and Bayer collaborate on alfimeprase

Aradigm seeks orphan drug designation for liposomal ciprofloxacin

Analgesic potential of new analogues of valproic acid

Pivotal phase III study evaluates cethromycin in community-acquired pneumonia

Zonagen receives IRB approval to begin phase III study of Androxal

Sangamo and Pfizer expand research collaboration

CancerVax and Micromet sign merger agreement

Lilly ruled to have breached oral PTH license agreements with Emisphere

Grants support work in diabetic kidney disease at University of Virginia

New therapeutic agents for inflammatory disorders disclosed in recent patents

VivaGel receives fast track status for HIV prevention

Thalomid pivotal multiple myeloma trial reaches prespecified interim endpoint

Bayer reports on the first potent and selective PDE9 inhibitor

Theravance prepares and tests novel beta2-adrenoceptor agonists for asthma

FDA approves quarterly intravenous Boniva for postmenopausal osteoporosis

FDA approval for subcutaneous immunoglobulin treatment Vivaglobin

NDA submission for CARDIOsphere to assess coronary artery disease

Taclonex approved for psoriasis vulgaris

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...